ClinicalTrials.gg
CompletedNCT03461068Updated Apr 18, 2019

Exogenous Ketones and Glucose Tolerance

A Phase 1 interventional study of Ketone monoester and Placebo in Ketones and Dietary Supplements, sponsored by University of British Columbia. Completed at 1 site in Canada. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-04-18.

Sponsored by University of British Columbia · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in Ketosis — 3 open to participants now, 3 under way, none of them phase 3. (R)-3-hydroxybutyl (R)-3-hydroxybutyrate · Ketosis.

Enrollment
7th of 11
15 · median 16
Started
2018
the only one that year
Phase 1
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
3 of 11
University of British Columbia

Among the 11 studies testing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in Ketosis, this one is the 7th largest by enrollment, is the only one that started in 2018, is the only one in phase 1, and was the 1st registered.

Ketosis

218 studies on the registry are indexed under Ketosis; 50 are open to participants now.

Browse Ketosis studies →

Open to participants now

3 of the 11 studies testing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in Ketosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About (R)-3-hydroxybutyl (R)-3-hydroxybutyrate

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 30 Ketosis studies recruiting now, 6 (20%) set no upper age limit and 22 (73%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in Ketosis, or all of them as a file.
02

Study summary

The ketone body beta-hydroxybutyrate is produced during prolonged fasting or when endogenous carbohydrate stores are depleted and can be used as an alternative fuel source. Exogenous beta-hydroxybutyrate, in the form of a ketone monoester, is proposed to have glucose-lowering potential but this has not been adequately studied. The purpose of this study is to determine whether supplementing with an acute dose of ketone monoester can improve the glycemic response to an oral glucose tolerance test in individuals with impaired fasting glucose.

03

Conditions studied

  • Ketones
  • Dietary Supplements

Browse trials for

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Not taking any medications affecting glucose metabolism.
  • Elevated fasting glucose level (5.6-6.9 mmol/L) OR >28 kg/m2 OR elevated waist circumference (>102 cm for males, >88 cm for females)

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with diabetes.
  • Diagnosed with heart disease.
  • Competitive endurance athlete (self-identified as engaged in specific endurance training in triathlon, cycling, or distance running and competing in races or competition)
  • Recent (last 3 months) or current consumption of a low-carbohydrate ketogenic diet
  • Current consumption of ketone supplements
  • Pregnant or planning to become pregnant during the study (if female)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Ketone monoester

    Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)

    Dietary Supplement: Ketone monoester

  • Placebo comparator
    Placebo

    Acute morning dose of flavour-matched placebo.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementKetone monoester

    Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.

  • Dietary supplementPlacebo

    Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.

06

What researchers measure

Primary outcomes

  1. Glucose area under the curve

    Area under the curve for glucose during oral glucose tolerance test

    Time frame: 2-hour

Secondary outcomes

  1. Insulin area under the curve

    Insulin area under the curve during oral glucose tolerance test

    Time frame: 2-hour

  2. Free fatty acids area under the curve

    Non-esterified fatty acids area under the curve during oral glucose tolerance test

    Time frame: 2-hour

  3. Caspase-1 activation

    Caspase-1 activation assessed before and after ketone or placebo ingestion in the morning

    Time frame: 15 minutes

  4. Inflammatory cytokines

    Inflammatory cytokines assessed before and after ketone or placebo ingestion in the morning

    Time frame: 15 minutes

  5. C-peptide area under the curve

    C-peptide area under the curve during oral glucose tolerance test

    Time frame: 2-hour

  6. GLP-1 area under the curve

    GLP-1 area under the curve during oral glucose tolerance test

    Time frame: 2-hour

  7. Glucagon area under the curve

    Glucagon area under the curve during oral glucose tolerance test

    Time frame: 2-hour

  8. Glucose incremental area under the curve

    Incremental area under the curve (above baseline) for glucose during oral glucose tolerance test

    Time frame: 2-hour

  9. Insulin incremental area under the curve

    Incremental area under the curve (above baseline) for insulin during oral glucose tolerance test

    Time frame: 2-hour

  10. 2-hr glucose level

    Plasma glucose assessed 2-hr after oral glucose tolerance test.

    Time frame: 2-hour

  11. Oral glucose sensitivity index

    Oral glucose sensitivity index derived from glucose and insulin values throughout the 2-hr oral glucose tolerance test

    Time frame: 2-hour

07

Study locations

1 site
  • University of British Columbia, Okanagan.
    Kelowna, British Columbia V1V 1V7, Canada
08

References and documents

Publications

  • Myette-Cote E, Caldwell HG, Ainslie PN, Clarke K, Little JP. A ketone monoester drink reduces the glycemic response to an oral glucose challenge in individuals with obesity: a randomized trial. Am J Clin Nutr. 2019 Dec 1;110(6):1491-1501. doi: 10.1093/ajcn/nqz232. PubMed 31599919 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Oct 2018, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2018
First posted
Mar 9, 2018
StartActual
Mar 26, 2018
Primary completionActual
Oct 3, 2018
CompletionActual
Oct 15, 2018
Last update
Apr 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03461068
Responsible party
Jonathan Little (Assistant Professor, University of British Columbia) — Principal investigator
First posted
Mar 9, 2018
Start date
Mar 26, 2018
Primary completion
Oct 3, 2018
Completion
Oct 15, 2018
Last update
Apr 18, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: (R)-3-hydroxybutyl (R)-3-hydroxybutyrate

Start the discussion